http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NO-20091936-L
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-64 |
| filingDate | 2009-05-19^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e97605457769fa6b183ccfe412c1dad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf6c9f26a5b80865f5e8a8e16bf9da7e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf6f95e435419961de1e54b110ab8a92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfea3b2a3effe615be00da52332d12f7 |
| publicationDate | 2009-07-14^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NO-20091936-L |
| titleOfInvention | 4-Imidazolines as TAAR ligands |
| abstract | The invention relates to compounds of formula I wherein R is hydrogen, lower alkyl or amino; X-R1 is -CH2-, -CH (lower alkoxy) - or -CH (OH) - and Y-R2 is -CH2, -CH (lower alkyl) -, -CH (lower alkoxy) - -O-, - S-, -S (O) -, -S (O) 2-, -CH (phenyl) - or -C (lower alkyl) 2-; or X-R1 is -NH- and Y-R2 is -CH2, -CH (lower alkyl) -, -CH (lower alkoxy) -, -CH (phenyl) - or -C (lower alkyl) 2-; Ar is phenyl, napthyl or benzofuranyl, wherein the rings are unsubstituted or substituted by one or more substituents selected from the group consisting of lower alkyl, lower alkyl substituted by halogen, halogen, lower alkoxy, lower alkoxy substituted by halogen, hydroxy, amino, di -alkylamino, morpholinyl, phenyl, benzyl or with O-benzyl; or pharmaceutically suitable acid addition salts. It has been found that the compounds of formula I have a good affinity for tracing amine associated receptors (TAARs), especially for TAAR1. The compounds can be used to treat depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological disorders such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, energy consumption and assimilation disorders, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm and cardiovascular disorders. |
| priorityDate | 2006-12-18^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 40 of 40.